SG Americas Securities LLC Acquires 17,407 Shares of Liquidia Corporation $LQDA

SG Americas Securities LLC lifted its holdings in shares of Liquidia Corporation (NASDAQ:LQDA) by 46.7% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 54,696 shares of the company’s stock after purchasing an additional 17,407 shares during the period. SG Americas Securities LLC owned about 0.06% of Liquidia worth $1,886,000 as of its most recent filing with the SEC.

A number of other large investors also recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Liquidia by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 37,681 shares of the company’s stock valued at $556,000 after buying an additional 1,700 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Liquidia by 10.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 861,231 shares of the company’s stock valued at $12,703,000 after acquiring an additional 82,955 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Liquidia by 15.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 121,756 shares of the company’s stock valued at $1,796,000 after acquiring an additional 16,022 shares during the period. Creative Planning boosted its holdings in Liquidia by 40.7% during the 2nd quarter. Creative Planning now owns 26,840 shares of the company’s stock valued at $334,000 after acquiring an additional 7,765 shares during the period. Finally, Swiss National Bank grew its position in Liquidia by 24.2% during the 2nd quarter. Swiss National Bank now owns 122,200 shares of the company’s stock worth $1,523,000 after acquiring an additional 23,800 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Insider Buying and Selling at Liquidia

In other Liquidia news, Director Stephen M. Bloch sold 62,550 shares of the company’s stock in a transaction on Friday, March 27th. The shares were sold at an average price of $35.94, for a total value of $2,248,047.00. Following the completion of the transaction, the director directly owned 2,188,935 shares in the company, valued at approximately $78,670,323.90. This represents a 2.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, General Counsel Russell Schundler sold 27,289 shares of Liquidia stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $37.43, for a total transaction of $1,021,427.27. Following the sale, the general counsel directly owned 579,394 shares in the company, valued at $21,686,717.42. The trade was a 4.50% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 293,398 shares of company stock worth $10,886,538. 26.50% of the stock is owned by corporate insiders.

Liquidia Stock Performance

NASDAQ LQDA opened at $37.68 on Monday. The stock has a market cap of $3.32 billion, a P/E ratio of -45.40 and a beta of 0.45. Liquidia Corporation has a fifty-two week low of $11.26 and a fifty-two week high of $46.67. The stock has a 50 day simple moving average of $37.38 and a two-hundred day simple moving average of $32.26. The company has a debt-to-equity ratio of 2.97, a quick ratio of 1.84 and a current ratio of 2.01.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Thursday, March 5th. The company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.07. Liquidia had a negative return on equity of 209.33% and a negative net margin of 43.53%.The firm had revenue of $92.02 million for the quarter, compared to analysts’ expectations of $87.49 million. Liquidia’s revenue for the quarter was up 3072.4% compared to the same quarter last year. On average, analysts forecast that Liquidia Corporation will post -1.51 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on LQDA. HC Wainwright boosted their price objective on Liquidia from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, March 6th. Oppenheimer raised their target price on shares of Liquidia from $16.00 to $19.00 and gave the stock an “underperform” rating in a report on Thursday, March 12th. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a report on Thursday, March 5th. Wells Fargo & Company increased their price target on shares of Liquidia from $44.00 to $51.00 and gave the company an “overweight” rating in a research report on Monday, March 23rd. Finally, Needham & Company LLC raised their price target on shares of Liquidia from $52.00 to $54.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $43.44.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).